FDA Approves Novo Nordisk's Norditropin for Treatment of Short Stature Associated with a Rare Genetic Disorder PRINCETON, N.J., June 1 -- Novo Nordisk today announced that Norditropin® ...
The daily injectable vosoritide (Voxzogo) appears promising for various genetic causes of short stature in children, new phase 2 trial data suggested. Vosoritide is a C-type natriuretic peptide analog ...
The "Biosimilar Growth Hormones Global Market Report 2020-30: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com’s offering. Major players in the biosimilar growth hormone ...
Please provide your email address to receive an email when new articles are posted on . Children with five genetic causes of short stature had height velocity increases of 3 cm or more with vosoritide ...
Please provide your email address to receive an email when new articles are posted on . GH has a long-documented track record of safety, although potential benefits and risks should always be ...
Although ISS is an important entity within pediatric endocrinology, its heterogeneous nature makes clinical management a challenge. A consensus group agreed that subcategorization of ISS on the basis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results